ODTX
Odyssey Therapeutics, Inc.
$16.69
-0.14 (-0.83%)
At close · Jul 10
Going-concern doubt
— cleared Jun 17, 2026
The latest filing states the doubt was alleviated.
“Upon closing of the IPO and concurrent private placement, and receipt of the associated cash proceeds, the Company believes the conditions that raised substantial doubt have been resolved. The Company believes that its existing cash, cash equivalents and marketable securities of $175.7 million as of March 31, 2026, together with the additional net proceeds of $288.7 million received from the IPO, concurrent private placement and the underwriters' exercise of the option to purchase additional shares of common stock, will be sufficient to allow the Company to fund operations at least twelve months from the date that the condensed consolidated financial statements are issued.”View the 10-Q filed Jun 17, 2026
Market Cap
$801.64M
Shares
48,031,320
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
No structured figures reported for this view yet.